Genomic test does not increase active surveillance acceptance for treating favorable-risk prostate cancer May 24, 2021 The results from a trial evaluating the Genomic Prostate Score did not find an increase in active surveillance acceptance amongst a population of predominantly Black men with favorable-risk prostate cancer.The Genomic Prostate Score (GPS) did not increase active surveillance acceptance compared with conventional risk counseling among patients with favorable-risk prostate cancer, according to data published in the Journal of Clinical Oncology.Read the full article here. Source: Matthew Fowler - Cancer Network About Prostate Cancer Genomic Testing Prostate Cancer News Testing & Diagnosis More for you
The results from a trial evaluating the Genomic Prostate Score did not find an increase in active surveillance acceptance amongst a population of predominantly Black men with favorable-risk prostate cancer.The Genomic Prostate Score (GPS) did not increase active surveillance acceptance compared with conventional risk counseling among patients with favorable-risk prostate cancer, according to data published in the Journal of Clinical Oncology.Read the full article here. Source: Matthew Fowler - Cancer Network
